フィンランドにおけるグラウコマ治療薬の払い戻し傾向の予測:2070年までのシステム動態モデルの更新
Eemil Lehtonen1, Anja Tuulonen2, Sanna Leinonen1,2
1Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland.
BMJ open ophthalmology
|August 24, 2025
まとめ
フィンランドでは 人口の高齢化により 2070年までに グラウコマの治療薬の使用が 57%増加する見込みです この研究は グラウコマ治療の将来の需要を予測する予測モデルを更新し,適応的なリソース配置の必要性を強調しています.
科学分野:
- 眼科と公衆衛生
- 視覚障害の流行病学
- 医療経済と資源配分
背景:
- グラウコマは不可逆的な失明の 主な原因で 世界の人口の高齢化により 罹患率が上昇しています
- グラウコマ治療薬の使用の正確な予測は 効果的な医療計画とリソースの配分に不可欠です
- 過去のモデルは,現在の人口動向を反映し,グラウコマ治療の将来の需要を予測するために更新する必要があります.
研究 の 目的:
- フィンランドにおける緑内障の薬剤使用者の予測のための2004年システムダイナミクス (SD) モデルの正確性を評価する.
- 2070年までの薬物使用者の予測のために,SDモデルを1990年から2023年までのデータで更新する.
- 純成長の減速の最近の傾向が一時的か持続するかを評価する.
主な方法:
- フィンランドの社会保険機関のグラウコマ治療薬使用者 (1986年-2023年) のデータを使用した.
- フィンランドの人口予測 (2021-2070年),人口変化,死亡率,移住を更新されたSDモデルに組み込んだ.
- 観測された傾向に対して予測を検証し,パラメータ化のために専門家のコンセンサスを使用した.
主要な成果:
- 更新されたモデルは,主に75歳以上の人口の増加に起因し,2070年までに緑内障の薬剤使用者が57%増加すると予測しています.
- このモデルは2015年から2023年にかけての ユーザー増加の減速を正確に捉えた.
- 2033年から2048年まで同様の成長の減速が予想され,その後は新たな加速が予想されます.
結論:
- 2070年までにフィンランドで グラウコマ治療の需要が増えるため 積極的な資源配分と継続的な監視が必要になります
- 需要の一時的な変動は,眼科の適応的な予測方法の必要性を強調しています.
- 更新されたモデルは,緑内障の治療の動向を監視し,国家医療資源の配分を伝えるための枠組みを提供します.
キーワード:
グラウコマ関連する概念動画
Glaucoma: Overview
749
Glaucoma is an eye condition characterized by increased intraocular pressure that damages the retina and optic nerve, leading to irreversible blindness if left untreated. The human eye has various components, including the cornea, iris, pupil, lens, and optic nerve. Aqueous humor is secreted by the epithelium of the ciliary body in the posterior chamber and flows through the trabecular meshwork and canal of Schlemm, maintaining normal intraocular pressure. The trabecular meshwork and the canal...
749
Open Angle Glaucoma: Treatment
561
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Drugs such as carbonic anhydrase inhibitors, α2- and...
561
Pharmacokinetic Models: Overview
1.1K
Pharmacokinetic models utilize mathematical analysis to achieve a detailed quantitative understanding of a drug's life cycle within the body. They are instrumental in simulating a drug's pharmacokinetic parameters, predicting drug concentrations over time, optimizing dosage regimens, linking concentrations with pharmacologic activity, and estimating potential toxicity.
There are three primary types of models: empirical, compartment, and physiological. Empirical models, with minimal...
There are three primary types of models: empirical, compartment, and physiological. Empirical models, with minimal...
1.1K
Analysis of Population Pharmacokinetic Data
382
Analysis of population pharmacokinetic data involves studying the behavior of drugs within diverse populations to understand their pharmacokinetic parameters. Traditional pharmacokinetic methods typically involve collecting samples from a few individuals and estimating these parameters. While these methods are commonly used, they have limitations in capturing the variability in drug response among individuals or heterogeneous populations. Population pharmacokinetics is employed to address these...
382
Model Approaches for Pharmacokinetic Data: Distributed Parameter Models
126
Pharmacokinetic models are mathematical constructs that represent and predict the time course of drug concentrations in the body, providing meaningful pharmacokinetic parameters. These models are categorized into compartment, physiological, and distributed parameter models.
The distributed parameter models are specifically designed to account for variations and differences in some drug classes. This model is particularly useful for assessing regional concentrations of anticancer or...
The distributed parameter models are specifically designed to account for variations and differences in some drug classes. This model is particularly useful for assessing regional concentrations of anticancer or...
126
Analysis Methods of Pharmacokinetic Data: Model and Model-Independent Approaches
224
Drug disposition in the body is a complex process and can be studied using two major approaches: the model and the model-independent approaches.
The model approach uses mathematical models to describe changes in drug concentration over time. Pharmacokinetic models help characterize drug behavior in patients, predict drug concentration in the body fluids, calculate optimum dosage regimens, and evaluate the risk of toxicity. However, ensuring that the model fits the experimental data accurately...
The model approach uses mathematical models to describe changes in drug concentration over time. Pharmacokinetic models help characterize drug behavior in patients, predict drug concentration in the body fluids, calculate optimum dosage regimens, and evaluate the risk of toxicity. However, ensuring that the model fits the experimental data accurately...
224


